Clinical trials in-a-dish for cardiovascular medicine.

🤖 Plain-English Summary

Cardiovascular diseases persist as a global health challenge that requires methodological innovation for effective drug development. It then explores challenges and emerging opportunities for the implementation of 'clinical trials in-a-dish'.

🔑 Key Findings

• Conventional pipelines relying on animal models suffer from high failure rates due to significant interspecies variation between humans and animal models.
• In response, the recently enacted Food and Drug Administration Modernization Act 2.0 encourages alternative approaches including induced pluripotent stem cells (iPSCs).
• Human iPSCs provide a patient-specific, precise, and screenable platform for drug testing, paving the way for cardiovascular precision medicine.

🔗 Related Resources